Faeth Therapeutics (FTH) Cash from Operations (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Cash from Operations came in at 10733000.0 in Q1 2026, down 51.3% YoY from 22037598.26 in Q1 2025, and down 177.77% on a QoQ basis from 3864000.0 in Q4 2025.
Faeth Therapeutics (FTH) Cash from Operations (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Cash from Operations data on file, last reported at 10733000.0 in Q1 2026.
- Quarterly Cash from Operations fell 51.3% year-over-year to 10733000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24092000.0 (changed 0.23% YoY) and the FY2025 annual result came in at 20453000.0, up 17.09% from the prior year.
- Cash from Operations eased to 10733000.0 in Q1 2026, from 3864000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 3586000.0 in Q3 2025 to a low of 11899000.0 in Q2 2022.
- A 5-year average of 7465000.0 and a median of 6803000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 96.78% — and 2024, when it jumped 38.79%.
- Tracing FTH's Cash from Operations over 5 years: stood at 9574000.0 in 2022, then soared by 35.63% to 6163000.0 in 2023, then climbed by 6.02% to 5792000.0 in 2024, then jumped by 33.29% to 3864000.0 in 2025, then slumped by 177.77% to 10733000.0 in 2026.
- The last three Cash from Operations figures came in at 10733000.0 (Q1 2026), 3864000.0 (Q4 2025), and 3586000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 728.46 Mn |
| 10 | Faeth Therapeutics | 181.71 Mn | 181.71 Mn | - | -15.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.67 Mn |
| Jun 30, 2026 | -15.67 Mn |
| Mar 31, 2026 | -10.73 Mn |
| Mar 31, 2026 | -10.73 Mn |
| Dec 31, 2025 | -3.86 Mn |
| Dec 31, 2025 | -3.86 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -5.91 Mn |
| Mar 31, 2025 | -7.09 Mn |
| Mar 31, 2025 | -7.09 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -5.79 Mn |
| Jun 30, 2024 | -5.79 Mn |
| Mar 31, 2024 | -7.62 Mn |
| Mar 31, 2024 | -7.62 Mn |